Vertex Pharmaceuticals Inc

Most Recent

  • uploads///revenue EE
    Earnings Report

    How Vertex’s Revenue and Earnings Surprised in 2Q16

    Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

    By Jillian Dabney
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    A Look at Incyte’s Valuation as of May 25

    Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally

    Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis

    Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.

    By Margaret Patrick
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///ANR
    Company & Industry Overviews

    Why Are Most Analysts Recommending a ‘Buy’ for Vertex?

    On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.

    By Jillian Dabney
  • uploads///PE multiple
    Company & Industry Overviews

    Why Is Vertex Pharmaceuticals’ Valuation at a Discount?

    On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).

    By Jillian Dabney
  • uploads///tesla renaissance technologies
    Consumer

    How Did Tesla Become Renaissance Technologies’ Gem?

    In the fourth quarter of 2019, Tesla was Renaissance Technologies’ second-largest holding. Renaissance is one of the largest hedge funds in the US.

    By Rabindra Samanta
  • uploads///microbiology _
    Company & Industry Overviews

    Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday

    On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.

    By Daniel Collins
  • uploads///SRPT EPS
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Recent Developments

    In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    How Is Sarepta Therapeutics Positioned in January?

    In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.

    By Daniel Collins
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///Biomarin
    Company & Industry Overviews

    How BioMarin Pharmaceutical’s Financials Look in November

    BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

    By Kenneth Smith
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///Vertex
    Company & Industry Overviews

    Vertex Pharmaceuticals Strengthens in the Cystic Fibrosis Space

    Vertex Pharmaceuticals (VRTX) develops medicines for life-threatening diseases and is presently focused on developing drugs for cystic fibrosis and sickle-cell disease, partnering with CRISPR Therapeutics (CRSP) for the latter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017.

    By Mike Benson
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • Company & Industry Overviews

    An Overview of Roche’s Immunology Drugs Pulmozyme and CellCept

    Roche’s CellCept generated revenues of 333.0 million Swiss francs in H1 2018 compared to 346.0 million Swiss francs in H1 2017.

    By Daniel Collins
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///addiction _
    Earnings Report

    How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?

    BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.

    By Daniel Collins
  • uploads///syringe _
    Company & Industry Overviews

    Incyte’s Valuations on July 6

    Incyte (INCY) posted revenues of $382.3 million in Q1 2018, a marginal decrease in YoY revenues compared to $384.1 million in Q1 2017.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares

    Ionis Pharmaceuticals (IONS), a therapeutics development leader, commercializes products in collaboration with other pharmaceutical companies.

    By Mike Benson
  • uploads///MEI
    Company & Industry Overviews

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Why Regeneron Pharmaceuticals’ Stock Price Fell

    Of the 27 analysts tracking Regeneron Pharmaceuticals (REGN) in March, five recommended a “strong buy” and six analysts recommended a “buy.”

    By Daniel Collins
  • uploads///FD
    Company & Industry Overviews

    Alexion Pharmaceuticals in 4Q17 and Fiscal 2017

    In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///rare diseases
    Company & Industry Overviews

    Inside Pfizer’s Rare Disease Segment Performance in 2017

    In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients

    Vertex Pharmaceuticals (VRTX) is currently involved in evaluating four triple combination regimens comprised of tezacaftor, ivacaftor, and one of the next-generation correctors.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline

    On January 10, 2018, Vertex Pharmaceuticals announced that Orkambi has secured regulatory approval from the European Commission to treat CF patients ages six to 11 years.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How’s Incyte’s Valuation in January 2018?

    Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in September 2017

    Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

    By Margaret Patrick
  • uploads///Defitelio
    Company & Industry Overviews

    How Is Jazz’s Defitelio Positioned after 2Q17?

    In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Behind Bioverativ’s Analyst Recommendations This September

    Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

    By Daniel Collins
  • uploads///Orkambi Kalydeco
    Company & Industry Overviews

    How Are Orkambi and Kalydeco Positioned after 2Q17?

    In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Healthy Profit Margins in 2017

    Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Robust Revenue Growth in 2017

    In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ–True North Therapeutics: Stronger Research Pipeline

    The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Focus on Innovative Combination Regimens

    On March 28, 2017, Vertex Pharmaceutical (VRTX) released data from a phase 3 trial, EVOLVE.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand

    Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.

    By Margaret Patrick
  • uploads///Chart  BIIB
    Miscellaneous

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///pipeline
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Clinical Pipeline

    In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.

    By Daniel Collins
  • uploads///Vertex Pharma Revenues
    Company & Industry Overviews

    Inside Vertex Pharmaceuticals’ Revenue Trend

    In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17

    To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Failed Healthcare Bill Will Impact the Pharmaceutical Industry

    Due to the failure of the new healthcare bill, major pharmaceutical companies witnessed a fall in their share prices from March 23, 2017, to March 27, 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis

    The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis

    Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics Expects Strong Revenue Growth

    United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///orkambis success
    Earnings Report

    Why Europe Is an Important Market for Vertex’s Orkambi

    Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.

    By Jillian Dabney
  • uploads///Orkambi
    Company & Industry Overviews

    Higher Discontinuations Are among Orkambi’s Concerns

    Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

    By Jillian Dabney
  • uploads///soliris opportunity
    Earnings Report

    How Significant Is Alexion’s Opportunity with Soliris?

    Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

    By Jillian Dabney
  • Basic Materials

    Why Has the JPMorgan Large-Cap Growth Fund Done so Poorly in 2016?

    The JPMorgan Large-Cap Growth Fund Class A (OLGAX) has dived by 3.9% YTD in 2016. This decline makes it the worst performer among our 12 funds.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    ALNY Reports Positive Results from Patisiran’s Open Label Extension Study

    On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.

    By Margaret Patrick
  • uploads///Pipeline
    Earnings Report

    How Does Vertex Plan to Expand Beyond Cystic Fibrosis?

    Vertex is trying to expand its product base beyond cystic fibrosis. It holds molecules in the oncology, respiratory, pain, spinal cord, and influenza spaces.

    By Jillian Dabney
  • Company & Industry Overviews

    Consumer Discretionary Drove Down OLGAX’s Returns in 1Q16

    OLGAX fell 6.4% in 1Q16. OLGAX fell 3.7% in the one-year period ended March 2016 and ranked ninth among its peer group.

    By David Ashworth
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///ADHD portfolio
    Company & Industry Overviews

    How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales

    Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Peers?

    Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Which Large-Cap Biotech Stock Fell the Most Last Week?

    Large-cap biotech stocks struggled during the week ending March 18, 2016. The large-cap stocks within the iShares Nasdaq Biotechnology ETF (IBB) suffered the most, falling 3.9% during the week.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Alexion Pushes Down IBB’s Performance

    Alexion Pharmaceuticals (ALXN) was the biggest loser among IBB’s large-cap stocks.

    By Peter Neil
  • uploads///total revenue
    Company & Industry Overviews

    What’s Vertex’s Strategy to Sustain the Cystic Fibrosis Market?

    Vertex Pharmaceuticals (VRTX) plans to continue to create high-value drugs for CF (cystic fibrosis). In 2015, CF product revenue stood at $983 million, a 110% increase in revenue.

    By Jillian Dabney
  • uploads///Anual drug projections
    Earnings Report

    Vertex Will Focus on Cystic Fibrosis Market in 2016

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for cystic fibrosis. In November 2015, it received approval from the European Commission to treat CF.

    By Jillian Dabney
  • uploads///Kalydeco projections
    Earnings Report

    Vertex’s Cystic Fibrosis Drugs and Their Controversial Prices

    Vertex Pharmaceuticals priced Kalydeco at $294,000 per year and recently increased the price to $311,000. Vertex is not the only company pricing its drugs at the higher end.

    By Jillian Dabney
  • uploads///Pipeline
    Earnings Report

    Will Vertex Pharmaceuticals’ Valuation Multiple Improve?

    These valuation multiples are susceptible to company- or industry-related material news. So any positive news results in a jump in the valuation multiple.

    By Jillian Dabney
  • uploads///Orkambi revenue projections
    Earnings Report

    Orkambi: Recent Addition to the Vertex Portfolio

    In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.

    By Jillian Dabney
  • uploads///Vertex financial projections
    Earnings Report

    What Are Wall Street’s Estimates for Vertex Pharmaceuticals?

    According to Wall Street analysts’ estimates, sales for Vertex Pharmaceuticals should be $408.8 million and $472.4 million for 4Q15 and 1Q16, respectively.

    By Jillian Dabney
  • uploads///Analyst recommendations
    Earnings Report

    Vertex Pharmaceuticals: What Are Analysts’ Estimates?

    Vertex Pharmaceuticals will report earnings for 4Q15 and fiscal 2015 on January 27, 2016. The company’s major focus area is hereditary disorder cystic fibrosis (or CF).

    By Jillian Dabney
  • uploads///Chart
    Macroeconomic Analysis

    Vertex Up 3.2% as Healthcare Sector Continued to Lure Investors

    XLV went up 1.2% on Tuesday, December 29. Its top stocks included Vertex Pharmaceuticals (VRTX), St Jude Medical (STJ), Cerner (CERN), and Biogen (BIIB).

    By Renee Blakely
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Vertex Pharmaceuticals Brings up the Rear among XBI’s Large-Caps on December 3

    Vertex Pharmaceuticals lost the most among the large-cap stocks on December 3, closing at $122.06—a decline of 6.4%.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Mylan Topped Large-Caps with New Launches, Share Repurchase Plan

    Mylan (MYL) stock rose 6.4% for the week ended November 20, 2015. It went up on a couple of new drug launches and a share repurchase plan.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    How Did the Biotechnology Subgroup of XLV Perform?

    Among all the subgroups in the Health Care Select Sector SPDR ETF, the biotechnology subgroup came out ahead, returning 3% on November 18, 2015.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    AbbVie Topped XBI’s Large-Cap Space

    AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.

    By Peter Neil
  • uploads///USD
    Macroeconomic Analysis

    US Dollar Falls Sharply as Non-Farm Payroll Disappoints

    The US Dollar Index fell sharply on the back of weak domestic labor data. It fell to 95.22 before regaining some strength towards the end of day.

    By David Meyer
  • uploads///Graph Part
    Company & Industry Overviews

    Biotechnology Traded below Moving Averages in Last Week of August

    Biotechnology and pharmaceuticals are the two largest subgroups of XLV. In the biotechnology subgroup, 100% of the stocks are trading below their 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Key Risks Vertex Pharmaceuticals Faces

    Biotechnology companies such as Regeneron, Alexion, Vertex, and Biogen have excessive business concentration risk, since they earn the majority of their revenues from a small number of drugs.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Illumina: Investor’s Overview of a Leading Biotechnology Company

    An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Cost Structure and EBITDA Margins

    While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Has Strong Research and Development Pipeline

    As part of its research and development, Vertex Pharmaceuticals (VRTX) has been actively exploring new cystic fibrosis (or CF) drugs as well as other indications for its existing drug Kalydeco.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Regeneron and Mylan End Up in Green for the Week

    Among the top ten stocks in IBB for the week ending September 18, only Illumina, Regeneron, and Mylan ended positively.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ New Drug Orkambi Receives FDA Approval

    On July 2, 2015, the FDA (U.S. Food and Drug Administration) approved Orkambi, a combination drug of lumacaftor and ivacaftor, for treating cystic fibrosis (or CF) patients.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Vertex Pharmaceuticals’ 3-Pronged Business Model

    Vertex Pharmaceuticals’ (VRTX) business model includes revenues in three areas: products, royalties, and collaboration. There’s significant variability in royalty and collaboration revenues.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.